Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9H0E7
UPID:
UBP44_HUMAN
Alternative names:
Deubiquitinating enzyme 44; Ubiquitin thioesterase 44; Ubiquitin-specific-processing protease 44
Alternative UPACC:
Q9H0E7; B2RDW3
Background:
Ubiquitin carboxyl-terminal hydrolase 44, also known as Deubiquitinating enzyme 44, plays a pivotal role in the spindle assembly checkpoint by mediating deubiquitination of CDC20, thus preventing premature anaphase onset. It stabilizes the MAD2L1-CDC20-APC/C complex, reinforcing the spindle assembly checkpoint and promoting deubiquitination of histones H2A and H2B. Additionally, it is involved in DNA repair processes and stabilizes FOXP3, enhancing regulatory T-cell lineage stability.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 44 could open doors to potential therapeutic strategies.